<?xml version="1.0"?>
<PC-AssayDescription
    xmlns="http://www.ncbi.nlm.nih.gov"
    xmlns:xs="http://www.w3.org/2001/XMLSchema-instance"
    xs:schemaLocation="http://www.ncbi.nlm.nih.gov ftp://ftp.ncbi.nlm.nih.gov/pubchem/specifications/pubchem.xsd"
>
  <PC-AssayDescription_aid>
    <PC-ID>
      <PC-ID_id>1265452</PC-ID_id>
      <PC-ID_version>1</PC-ID_version>
    </PC-ID>
  </PC-AssayDescription_aid>
  <PC-AssayDescription_aid-source>
    <PC-Source>
      <PC-Source_db>
        <PC-DBTracking>
          <PC-DBTracking_name>ChEMBL</PC-DBTracking_name>
          <PC-DBTracking_source-id>
            <Object-id>
              <Object-id_str>1542134</Object-id_str>
            </Object-id>
          </PC-DBTracking_source-id>
        </PC-DBTracking>
      </PC-Source_db>
    </PC-Source>
  </PC-AssayDescription_aid-source>
  <PC-AssayDescription_name>Inhibition of c-Raf in human A549 cells assessed as downregulation of phosphorylated ERK1/2 expression after 48 hrs by Western blot analysis</PC-AssayDescription_name>
  <PC-AssayDescription_description>
    <PC-AssayDescription_description_E>Title: Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.</PC-AssayDescription_description_E>
    <PC-AssayDescription_description_E></PC-AssayDescription_description_E>
    <PC-AssayDescription_description_E>Abstract: Through a structure-based molecular hybridization approach, a series of novel quinazolinyl-diaryl urea derivatives were designed, synthesized, and screened for their in vitro antiproliferative activities against three cancer cell lines (HepG2, MGC-803, and A549). Six compounds (7 g, 7 m, 7 o, 8 e, 8 g, and 8 m) showed stronger activity against a certain cell line compared with the positive reference drugs sorafenib and gefitinib. Among the six compounds, 8 g exhibited the strongest activity. In particular, compound 8 g induced A549 apoptosis, arrested cell cycle at the G0/G1 phase, elevated intracellular reactive oxygen species level, and decreased mitochondrial membrane potential. This compound can also effectively regulate the expression of apoptosis- and cell cycle-related proteins, and influence the Raf/MEK/ERK pathway. Molecular docking and structure-activity relationship analyses revealed that it can bind well to the active site of the receptor c-Raf, which was consistent with the biological data. Therefore, compound 8 g may be a potent antitumor agent, representing a promising lead for further optimization.</PC-AssayDescription_description_E>
  </PC-AssayDescription_description>
  <PC-AssayDescription_comment>
    <PC-AssayDescription_comment_E>Journal: Eur. J. Med. Chem.</PC-AssayDescription_comment_E>
    <PC-AssayDescription_comment_E>Year: 2016</PC-AssayDescription_comment_E>
    <PC-AssayDescription_comment_E>Volume: 107</PC-AssayDescription_comment_E>
    <PC-AssayDescription_comment_E>First Page: 12</PC-AssayDescription_comment_E>
    <PC-AssayDescription_comment_E>Last Page: 25</PC-AssayDescription_comment_E>
    <PC-AssayDescription_comment_E>DOI: 10.1016/j.ejmech.2015.10.045</PC-AssayDescription_comment_E>
    <PC-AssayDescription_comment_E></PC-AssayDescription_comment_E>
    <PC-AssayDescription_comment_E>Target ChEMBL ID: CHEMBL1906</PC-AssayDescription_comment_E>
    <PC-AssayDescription_comment_E>ChEMBL Target Name: Serine/threonine-protein kinase RAF</PC-AssayDescription_comment_E>
    <PC-AssayDescription_comment_E>ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain</PC-AssayDescription_comment_E>
    <PC-AssayDescription_comment_E>Relationship Type: D - Direct protein target assigned</PC-AssayDescription_comment_E>
    <PC-AssayDescription_comment_E>Confidence: Direct single protein target assigned</PC-AssayDescription_comment_E>
  </PC-AssayDescription_comment>
  <PC-AssayDescription_xref>
    <PC-AnnotatedXRef>
      <PC-AnnotatedXRef_xref>
        <PC-XRefData>
          <PC-XRefData_taxonomy>9606</PC-XRefData_taxonomy>
        </PC-XRefData>
      </PC-AnnotatedXRef_xref>
      <PC-AnnotatedXRef_comment>Homo sapiens</PC-AnnotatedXRef_comment>
    </PC-AnnotatedXRef>
    <PC-AnnotatedXRef>
      <PC-AnnotatedXRef_xref>
        <PC-XRefData>
          <PC-XRefData_pmid>26560049</PC-XRefData_pmid>
        </PC-XRefData>
      </PC-AnnotatedXRef_xref>
      <PC-AnnotatedXRef_type value="pcit">1</PC-AnnotatedXRef_type>
    </PC-AnnotatedXRef>
    <PC-AnnotatedXRef>
      <PC-AnnotatedXRef_xref>
        <PC-XRefData>
          <PC-XRefData_dburl>http://www.ebi.ac.uk/chembldb/</PC-XRefData_dburl>
        </PC-XRefData>
      </PC-AnnotatedXRef_xref>
    </PC-AnnotatedXRef>
    <PC-AnnotatedXRef>
      <PC-AnnotatedXRef_xref>
        <PC-XRefData>
          <PC-XRefData_asurl>http://www.ebi.ac.uk/chembldb/index.php/assay/inspect/1542134</PC-XRefData_asurl>
        </PC-XRefData>
      </PC-AnnotatedXRef_xref>
    </PC-AnnotatedXRef>
    <PC-AnnotatedXRef>
      <PC-AnnotatedXRef_xref>
        <PC-XRefData>
          <PC-XRefData_protein-gi>125651</PC-XRefData_protein-gi>
        </PC-XRefData>
      </PC-AnnotatedXRef_xref>
    </PC-AnnotatedXRef>
  </PC-AssayDescription_xref>
  <PC-AssayDescription_results>
    <PC-ResultType>
      <PC-ResultType_tid>1</PC-ResultType_tid>
      <PC-ResultType_name>Standard Type</PC-ResultType_name>
      <PC-ResultType_description>
        <PC-ResultType_description_E>Standardized activity type (e.g. IC50 rather than Ic-50/Ic50/ic50/ic-50)</PC-ResultType_description_E>
      </PC-ResultType_description>
      <PC-ResultType_type value="string">4</PC-ResultType_type>
    </PC-ResultType>
    <PC-ResultType>
      <PC-ResultType_tid>2</PC-ResultType_tid>
      <PC-ResultType_name>Activity Comment</PC-ResultType_name>
      <PC-ResultType_description>
        <PC-ResultType_description_E>Additional comments</PC-ResultType_description_E>
      </PC-ResultType_description>
      <PC-ResultType_type value="string">4</PC-ResultType_type>
    </PC-ResultType>
  </PC-AssayDescription_results>
  <PC-AssayDescription_revision>1</PC-AssayDescription_revision>
  <PC-AssayDescription_target>
    <PC-AssayTargetInfo>
      <PC-AssayTargetInfo_name>RAF proto-oncogene serine/threonine-protein kinase</PC-AssayTargetInfo_name>
      <PC-AssayTargetInfo_mol-id>125651</PC-AssayTargetInfo_mol-id>
      <PC-AssayTargetInfo_molecule-type value="protein">1</PC-AssayTargetInfo_molecule-type>
      <PC-AssayTargetInfo_organism>
        <BioSource>
          <BioSource_org>
            <Org-ref>
              <Org-ref_db>
                <Dbtag>
                  <Dbtag_db>taxon</Dbtag_db>
                  <Dbtag_tag>
                    <Object-id>
                      <Object-id_id>9606</Object-id_id>
                    </Object-id>
                  </Dbtag_tag>
                </Dbtag>
              </Org-ref_db>
              <Org-ref_orgname>
                <OrgName>
                  <OrgName_name>
                    <OrgName_name_binomial>
                      <BinomialOrgName>
                        <BinomialOrgName_genus>Homo sapiens</BinomialOrgName_genus>
                      </BinomialOrgName>
                    </OrgName_name_binomial>
                  </OrgName_name>
                </OrgName>
              </Org-ref_orgname>
            </Org-ref>
          </BioSource_org>
        </BioSource>
      </PC-AssayTargetInfo_organism>
      <PC-AssayTargetInfo_descr>Serine/threonine-protein kinase RAF</PC-AssayTargetInfo_descr>
      <PC-AssayTargetInfo_comment>
        <PC-AssayTargetInfo_comment_E>Protein Accession: P04049</PC-AssayTargetInfo_comment_E>
      </PC-AssayTargetInfo_comment>
    </PC-AssayTargetInfo>
  </PC-AssayDescription_target>
  <PC-AssayDescription_project-category value="literature-extracted">7</PC-AssayDescription_project-category>
  <PC-AssayDescription_assay-group>
    <PC-AssayDescription_assay-group_E>PMID: 26560049</PC-AssayDescription_assay-group_E>
  </PC-AssayDescription_assay-group>
</PC-AssayDescription>
